Non-V600E BRAF mutations and treatment for hairy cell leukemia

2.

Tiacci

E

,

Trifonov

V

,

Schiavoni

G

, et al.

BRAF mutations in hairy-cell leukemia

.

N Engl J Med

.

2011

;

364

(

24

):

2305

-

2315

.

3.

Else

M

,

Dearden

CE

,

Matutes

E

, et al.

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

.

Br J Haematol

.

2009

;

145

(

6

):

733

-

740

.

4.

Arons

E

,

Suntum

T

,

Stetler-Stevenson

M

,

Kreitman

RJ

.

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

.

Blood

.

2009

;

114

(

21

):

4687

-

4695

.

5.

Kreitman

RJ

,

Wilson

W

,

Calvo

KR

, et al.

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

.

Clin Cancer Res

.

2013

;

19

(

24

):

6873

-

6881

.

6.

Chihara

D

,

Arons

E

,

Stetler-Stevenson

M

, et al.

Long term follow-up of a phase II study of cladribine with concurrent rituximab in patients with hairy cell leukemia variant

.

Blood Adv

.

2021

;

5

(

23

):

4807

-

4816

.

7.

Tiacci

E

,

Park

JH

,

De Carolis

L

, et al.

Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia

.

N Engl J Med

.

2015

;

373

(

18

):

1733

-

1747

.

8.

Tiacci

E

,

De Carolis

L

,

Simonetti

E

, et al.

Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia

.

N Engl J Med

.

2021

;

384

(

19

):

1810

-

1823

.

9.

Tiacci

E

,

De Carolis

L

,

Simonetti

E

, et al.

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

.

Leukemia

.

2021

;

35

(

11

):

3314

-

3318

.

10.

Kreitman

RJ

,

Moreau

P

,

Ravandi

F

, et al.

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia

.

Blood

.

2023

;

141

(

9

):

996

-

1006

.

11.

Langabeer

SE

,

O’Brien

D

,

McElligott

AM

,

Lavin

M

,

Browne

PV

.

BRAF V600E-negative hairy cell leukaemia

.

Case Rep Hematol

.

2013

;

2013

:

513049

.

12.

Langabeer

SE

.

Non-canonical BRAF variants and rearrangements in hairy cell leukemia

.

Oncol Res

.

2024

;

32

(

9

):

1423

-

1427

.

13.

Schnittger

S

,

Bacher

U

,

Haferlach

T

, et al.

Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia

.

Blood

.

2012

;

119

(

13

):

3151

-

3154

.

14.

Xi

L

,

Arons

E

,

Navarro

W

, et al.

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

.

Blood

.

2012

;

119

(

14

):

3330

-

3332

.

15.

Waterfall

JJ

,

Arons

E

,

Walker

RL

, et al.

High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias

.

Nat Genet

.

2014

;

46

(

1

):

8

-

10

.

16.

Tschernitz

S

,

Flossbach

L

,

Bonengel

M

,

Roth

S

,

Rosenwald

A

,

Geissinger

E

.

Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias

.

Br J Haematol

.

2014

;

165

(

4

):

529

-

533

.

17.

Maitre

E

,

Macro

M

,

Troussard

X

.

Hairy cell leukaemia with unusual BRAF mutations

.

J Cell Mol Med

.

2023

;

27

(

17

):

2626

-

2630

.

18.

Thomas

C

,

Amanuel

B

,

Finlayson

J

,

Grieu-Iacopetta

F

,

Spagnolo

DV

,

Erber

WN

.

BRAF mutation detection in hairy cell leukaemia from archival haematolymphoid specimens

.

Pathology

.

2015

;

47

(

4

):

349

-

354

.

19.

Matsumoto

K

,

Kakazu

N

,

Imataki

O

,

Kondo

A

,

Kanaji

N

,

Kadowaki

N

.

Hairy cell leukaemia with an IGH-BRAF fusion gene

.

Br J Haematol

.

2023

;

202

(

6

):

e67

-

e70

.

20.

Thompson

ER

,

Lim

KJC

,

Kuzich

JA

, et al.

Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia

.

Leuk Lymphoma

.

2020

;

61

(

8

):

2024

-

2026

.

21.

Liau

NPD

,

Wendorff

TJ

,

Quinn

JG

, et al.

Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization

.

Nat Struct Mol Biol

.

2020

;

27

(

2

):

134

-

141

.

22.

Chihara

D

,

Arons

E

,

Stetler-Stevenson

M

, et al.

Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia

.

J Clin Oncol

.

2020

;

38

(

14

):

1527

-

1538

.

23.

Grever

MR

,

Abdel-Wahab

O

,

Andritsos

LA

, et al.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

.

Blood

.

2017

;

129

(

5

):

553

-

560

.

24.

Ravandi

F

,

O'Brien

S

,

Jorgensen

J

, et al.

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

.

Blood

.

2011

;

118

(

14

):

3818

-

3823

.

25.

Chihara

D

,

Kantarjian

H

,

O'Brien

S

, et al.

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

.

Br J Haematol

.

2016

;

174

(

5

):

760

-

766

.